Abstract Autosomal dominant hypocalcemia can be caused by activating mutations of the calcium-sensing receptor (CaSR) gene. We experienced two patients (proband and her daughter) with hypocalcemia caused by a missense mutation of the CaSR gene. The proband, aged 25, showed hypocalcemia and hypoparathyroidism from infancy. She had been diagnosed as having idiopathic hypoparathyroidism and had been treated with calcitriol. She gave birth to a female infant at age 24 years. Her daughter was found to have hypocalcemia (Ca, 6.6 mg/dl), without seizure or tetany, when she was 7 months old. DNA analysis of their CaSR genes showed a novel heterozygous mutation at codon 129 (TGC-to-AGC) with substitution of cysteine for serine (C129S). Familial examination revealed that this mutation had occurred de-novo in the proband. Wild-type and mutant (C129S) CaSR cDNA were transfected into HEK293 cells, and intracellular calcium concentrations were measured with a fluorescent calcium indicator. HEK cells transfected with the C129S mutant CaSR gene showed a larger increase in intracellular calcium concentration in response to the change in the extracellular calcium concentration than HEK cells transfected with the wild-type receptor. We conclude that the C129S mutation in the CaSR gene observed in these patients causes autosomal dominant hypocalcemia.
Introduction
The calcium-sensing receptor (CaSR) is a member of the seven-transmembrane domain G-protein-coupled receptor superfamily. With mutations of the CaSR gene, hypercalcemia or hypocalcemia can occur Garrett et al. 1995) . Mutations in the CaSR gene that cause gain in the receptor function have been reported in patients with autosomal dominant hypocalcemia (Mancilla et al.1997; Lovlie et al. 1996; Pearce et al. 1996b; Okazaki et al. 1999) and in sporadic hypocalcemia (Baron et al. 1996; De Luka et al. 1997) . Even when extracellular calcium concentration declines, CaSR with activating mutations inappropriately suppresses the secretion of parathyroid hormone, which increases serum calcium levels, resulting in hypocalcemia. In previous reports, mutations that cause autosomal dominant hypocalcemia have been detected in the extacellular domain of the proximal amino-terminal region or the transmembrane region of the receptor. We experienced familial hypocalcemia (proband and her daughter), and confirmed by DNA analysis that a novel mutation at codon129 of CaSR had occurred in the proband, and was transmitted to her daughter.
Patients and methods
The proband (case 1) was a 25-year-old woman. She had manifested hypocalcemia in infancy. From seven months of age, she had experienced convulsions and was diagnosed as having epilepsy. When she was 8 years old, she visited our hospital and showed hypocalcemia (Ca, 6.0mg/dl) and hyperphosphatemia (inorganic[i]P, 10.2mg/dl). EllsworthHoward test showed a normal response of urinary cyclic adenosine morophosphate (cAMP) excretion. Thus, she was diagnosed as having idiopathic hypoparathyroidism, and calcitriol therapy was started. When she was 19 years old, she had nephrocalcinosis and her serum creatinine level was increased, to 1.3mg/dl. At the age of 24 years, she gave birth to a female infant (case 2). The daughter was asymptomatic during early infancy. When she was 7 months old, she was found to have hypocalcemia (Ca, 6.6 mg/dl) and hyperphosphatemia (iP, 9.5 mg/dl). Her intact parathyroid hormone (PTH) level was below the normal range (Ͻ5 pg/ ml). The urinary calcium/creatinine ratio in the proband and her daughter exceeded 0.21, when serum calcium concentrations were 7.0 mg/dl in case 1 and 8.4 mg/dl in case 2.
Because the disease was apparently transmitted in a dominant form, we performed DNA analysis of the CaSR gene after obtaining written informed consent from the patient for herself and her daughter. Lymphocytes were collected from heparinized peripheral blood samples and DNA was extracted with the Sepa Gene kit (Sanko Jyunyaku, Tokyo, Japan). Exon 2 to exon 7 of the CaSR gene, which codes the entire the CaSR, were amplified by the polymerase chain reaction (PCR) procedure (Pollak et al. 1993) . The PCR products were analyzed with the ABI PRISM 310 Genetic Analyzer (PE Applied Biosystems, Foster City, CA, USA), and the entire sequence of the coding region of the CaSR gene was determined. For expression experiments, wild-type CaSR cDNA was inserted into a pcDNA3 vector (pcDNA3CaSR) (Invitrogen, Carlbad, CA, USA), and a mutant expression plasmid was constructed by in-vitro site-directed mutagenesis (Gene Editor in vitro Site-Directed Mutagenesis System, Promega, Madison, WI, USA) to replace cysteine-129 to serine (pcDNA3CaSR-C129S). HEK293 cells were transfected with the wild-type or the mutant plasmid, and stable cell lines expressing receptors were selected by adding G418 to the culture medium. We measured the cytosolic calcium changes in single cells as described previously (Miyauchi et al. 2000) . Briefly, HEK293 cells expressing either wild-type or mutant CaSR were cultured for 1 to 2 days on glass cover slips and loaded with 5 µM fura 2-AM (Dojindo Laboratories, Kumamoto, Japan), a fluorescent calcium indicator, for 1 h at 25°C in the bath solution (126mM NaCl, 5 mM KCl, 1 mM mgCl 2 , 0.5 mM CaCl 2 , 20 mM Na-hydroxyethylpiperazine ethanesulfonic acid [HEPES] (pH 7.4), and 0.5% bovine serum albumin). The measuring chamber was mounted on a microfluorometric system, and images were collected at wavelengths of 340 nm (F340) and 360 nm (F360). The F340/F360 ratio, constructed after background image subtraction, disclosed the intracellular Ca 2ϩ ([Ca 2ϩ ] i ) localization. The average cell [Ca 2ϩ ] i values were calculated from the calibration curve as previously described (Miyauchi et al. 2000) . High extracellular Ca 2ϩ challenge was performed by replacing the medium with other media at various Ca 2ϩ concentrations.
Results and discussion
DNA analysis revealed that the CaSR gene in both the proband and her daughter had a heterozygous mutation in exon 2 at codon 129 (TGC-to-AGC) (Fig. 1A) that caused a substitution of the amino acid cysteine to serine. This substitution created an AlwN1 restriction site. Examination of the parents and the brother of the proband (Fig. 1B) with enzyme-based and direct sequence analysis revealed that this mutation had occurred in the proband de novo. We did not find this mutation in 100 alleles in 50 healthy volunteers without hypocalcemia. In addition, this nucleotide change did not exist in more than 100 normal subjects (Heath et al.1996) (Fig. 2) . Thus, to our knowledge, this is the first report that the mutation at cysteine-129 of the CaSR gene (Fig. 3) causes autosomal dominant hypocalcemia.
Extracellular calcium concentration is regulated mainly by PTH secretion from the parathyroid gland. CaSR senses extracellular calcium concentration and regulates PTH synthesis. PTH secretion is inappropriately suppressed with lower extracellular calcium concentration by activating mutations of CaSR. Although, at present, it is still not clear whether CaSR exists as a dimer in the cell membrane or not , Watanabe et al. (1998) demonstrated that the co-expression of the wild-type and the activating mutant CaSR shifted the set-point of the extracellular calcium concentration to almost equivalent to that observed Fig. 1 . A DNA analysis of the CaSR gene in case 1. Entire coding regions of the CaSR gene were amplified by polymerase chain reaction (PCR) from the genomic DNA of the patients, and the DNA sequence was determined by the direct sequence method. A heterozygous mutation at codon 129 (TGC-to-AGC) was revealed in case 1. The same mutation was seen in case 2. B Pedigree of the patients. Mutation of the CaSR gene was detected only in the affected members of the family (the proband and her daughter) with mutant receptor alone. Taken together, these findings indicate that the activating mutation of the CaSR gene in one allele causes the hypocalcemia inherited in autosomal dominant form.
The extracellular domain of CaSR does not contain the consensus sequences proposed for high-affinity Ca 2ϩ binding sites, but a low-affinity Ca 2ϩ binding site does exist in this domain (Brown et al.1993 ). The precise mechanism by which CaSR transmits the change in the extracellular calcium concentration is unknown, but the low-affinity Ca 2ϩ binding site may play a significant role. Point mutations of Fig. 3 . Portions of activating mutations in CaSR. Activating mutations reported previously existed at the N-terminal in the extracellular domain or in the transmembrane domain. The mutation in our cases (probond and her daughter) exists at the N-terminal in the extracellular domain glutamic acid-127 (Pollak et al.1994 ) and phenylalanine-128 (Pearce et al. 1996a) were previously reported to cause autosomal dominant hypocalcemia. Because the mutation we report here was located at codon 129, this region seems to be significant in regard to the binding to extracellular calcium. Previously, hypocalcemia was reported to be more severe in patients with mutations in the transmembrane domain than in those with mutations in the extracellular domain of the CaSR gene (Watanabe et al. 1998 ). Considering that the proband presented here apparently manifested more severe symptoms than her daughter, the severity of autosomal dominant hypocalcemia seems to be determined not only by the type of mutation but also by other factors, such as the calcium nutritional status.
In conclusion, the novel point mutation at cysteine-129 in the extracellular domain of CaSR causes autosomal dominant hypocalcemia, and this result indicates that this amino acid plays an important role in binding to extracellular calcium ions.
